altretamine indications/contra

Stem definitionDrug idCAS RN
141 645-05-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • altretamine
  • hexalen
  • hexamethylmelamine
  • hexylen
The precise mechanism by which altretamine capsules exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine capsules resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine capsules and its metabolites have been negative. Altretamine capsules has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement for cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.
  • Molecular weight: 210.29
  • Formula: C9H18N6
  • CLOGP: 1.66
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 0
  • TPSA: 48.39
  • ALOGS: -1.83
  • ROTB: 3

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1990 FDA EISAI INC

FDA Adverse Event Reporting System

None

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01XX03 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D009676 Noxae

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Malignant tumor of ovary indication 363443007 DOID:2394
Mood swings contraindication 18963009
Ataxia contraindication 20262006
Leukopenia contraindication 84828003 DOID:615
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006 DOID:574
Bone marrow depression contraindication 307762000
Vertigo contraindication 399153001
Breastfeeding (mother) contraindication 413712001
Unconscious contraindication 418107008
Severe Bone Marrow Depression contraindication

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.66 Basic
pKa2 3.04 Basic
pKa3 0.46 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Cytochrome P450 1A2 Enzyme IC50 5.40 DRUG MATRIX
DNA DNA OTHER SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

scroll-->
IDSource
DB00488 DRUGBANK_ID
4019574 VUID
N0000147673 NUI
C0019453 UMLSCUI
7112 IUPHAR_LIGAND_ID
D02841 KEGG_DRUG
2123 PUBCHEM_CID
5296 RXNORM
387385000 SNOMEDCT_US
69879000 SNOMEDCT_US
4156 MMSL
d01372 MMSL
4019574 VANDF
N0000007266 NDFRT
N0000147673 NDFRT
003567 NDDF
CHEMBL1455 ChEMBL_ID
CHEBI:24564 CHEBI
D006585 MESH_DESCRIPTOR_UI
Q8BIH59O7H UNII
4825 INN_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Hexalen HUMAN PRESCRIPTION DRUG LABEL 1 62856-001 CAPSULE 50 mg ORAL NDA 14 sections